MBP and myeloid sarcoma: To investigate the effect of S18 treatment on generation of MBP(85–99) specific immune-reactivities in-situ, SJL/J mice were co-immunized with MBP(85–99) (100 μg) and 400 μg of S18, J5 or control peptide (Nase(101–120), unrelated to etiology of MS) in CFA.